Oncologic Outcomes of Total Length Gleason Pattern 4 on Biopsy in Men with Grade Group 2 Prostate Cancer.
Marlon Lakmal PereraMelissa J AsselNicole E BenfanteAndrew J VickersVictor E ReuterSigrid CarlssonVincent LaudoneKarim A TouijerJames A EasthamPeter T ScardinoSamson W FineBehfar EhdaiePublished in: The Journal of urology (2022)
These findings support further studies on GP4 quantification in addition to the ratio of GP3 and GP4 to classify prostate cancer risk. Research should also be conducted on whether GP4 quantification could provide a surrogate endpoint for disease progression for trials in active surveillance.